Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Dicerna Pharmaceuticals (NASDAQ:DRNA) announces its next round of earnings Wednesday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.
Earnings and Revenue
Sell-side analysts are expecting Dicerna's loss per share to be near 42 cents on sales of $1.78 million.
In the same quarter last year, Dicerna Pharmaceuticals reported a loss per share of 86 cents on sales of $252,000. Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | -0.38 | -0.65 | -0.69 | -0.6 |
| EPS Actual | -0.3 | -0.9 | -0.92 | -0.86 |
Stock Performance
Over the last 52-week period, shares are up 291.11 percent. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Dicerna Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!